References in periodicals archive ?
The L-T4 dose was reduced to 50 [micro]g/day and TFT results were maintained within reference intervals.
TSH lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid, and euthyroid on L-T4 therapy patients.
Therefore, the bone marrow-absorbed dose after treatment with RAI would be expected to be lower for patients given rhTSH, which is protective for hypothyroidism and additionally may reduce the half-life of RAI, than for patients subjected to L-T4 withdrawal (12-14).
Tightening of potency specifications will alleviate some, but not all, of the measured variability among L-T4 products, and it does nothing to address the flawed method by which FDA determines bioequivalence of the drugs.
As of January 2007, four branded oral L-T4 products were available in the United States: levothyroxine sodium (Unithroid, Levoxyl, Synthroid and Levothroid).
Generally, you should stick with one L-T4 product for treating hypothyroidism, generally a branded L-T4.
Bioavailability of L-T4 was reduced by 40% regardless of whether subjects took the drug shortly before or immediately after the meal.
As of January 2005, seven branded orally administered L-T4 products have been approved by the U.
In other words, patients who have been lax about taking their L-T4 separate from meals may require a dose correction of up to 40% of administered drug in order to optimize therapy, he said.
The results merit further studies to evaluate the potential therapeutic substitution of, or combination with L-T4 for the treatment of hypothyroidism.
Synthetic L-T4 as a therapeutic agent was first used in the 1950s and was widely adopted as the primary agent for thyroid hormone replacement, replacing the natural desiccated thyroid extract that had been used over the previous 50-year period [2].
L-T4 is taken daily to restore the body's hormone balance, and most patients report feeling less tired within a couple of weeks of starting the medication.